LBP potential is there but progress tempered by regulatory hurdles, predicts GlobalData 04-Aug-2021 By Will Chu Live biotherapeutic products (LBPs) have been hailed as the answer for patients suffering from Irritable Bowel Syndrome (IBS), says GlobalData, which cite a lack of defined regulations as the main barrier to progress.